The stakes are considerable. According to the International Diabetes Federation, type 2 diabetes affected 11.1 percent of the global population aged 20 to 74 in 2024, but that figure climbs above 20 percent among people aged 65 to 99. Aging and obesity are the two dominant risk factors for impaired glucose tolerance and type 2 diabetes, and insulin resistance is a central contributor to disease progression. Yet while the beta cell has been exhaustively studied in this context, the alpha cell, which raises blood glucose by triggering hepatic glucose production through glucagon, has remained largely terra incognita in aging research.

To disentangle the effects of aging itself from those of insulin resistance, the team studied 20-month-old male mice divided into two groups based on insulin sensitivity, measured by the QUICKI index, alongside young adult controls. Remarkably, both aged groups, whether insulin sensitive or resistant, developed hyperglucagonemia and showed exaggerated glucagon responses during an arginine tolerance test. Fasting glucagon levels correlated negatively with insulin sensitivity across all animals, indicating that insulin resistance further amplifies the problem, but the core defect emerged with age alone.

Morphological analysis of the pancreas revealed a likely partial explanation: alpha cell area and mass increased progressively in aged animals, with the expansion most pronounced in insulin-resistant mice. This growth did not stem from hypertrophy or new islet formation, since alpha cell size and islet density remained unchanged. Instead, the data suggest an accumulation of long-lived alpha cells formed earlier in life. Intriguingly, alpha cell proliferation actually declined with age, and apoptosis, while remaining very low overall, ticked up slightly in insulin-resistant animals, painting a picture of a slowly expanding, slowly turning-over cell population.

The architecture of the islets themselves also shifted. Insulin-resistant aged mice showed a reduced proportion of insulin-positive cells and an increased percentage of glucagon-positive cells, along with more alpha cells straying from their characteristic position at the islet periphery into the core. Because islet organization is critical for the paracrine signals that regulate hormone secretion, these spatial changes could directly undermine the inhibitory cues that normally restrain glucagon release when glucose is abundant.

Functional testing confirmed that loss of control. In isolated islets exposed to low glucose, which stimulates glucagon secretion, aged cells performed normally. But when the researchers applied the two physiological brakes, high glucose and insulin, islets from insulin-resistant aged mice failed to suppress glucagon significantly, achieving only about 24 percent inhibition with glucose and 28 percent with insulin, compared with roughly 43 and 54 percent in young controls. Patch-clamp recordings showed that voltage-gated potassium and calcium currents and the exocytotic machinery were largely preserved, pointing the finger at impaired glucose sensing, metabolism, or paracrine signaling rather than a generalized secretory failure.

Transmission electron microscopy uncovered the most striking cellular signature: a markedly enlarged endoplasmic reticulum in alpha cells from both aged groups, a classic hallmark of ER stress. The secretory granules themselves appeared largely normal in number, density, and maturation, though insulin-resistant mice showed slightly larger granules and fewer docked at the membrane, possible signs of early exhaustion from compensatory hypersecretion. Reanalysis of single-cell RNA sequencing data from more than 300,000 islet cells reinforced the finding, revealing upregulated expression of ER stress and unfolded protein response genes, including Hspa5, Atf6, Ddit3, and Xbp1, in alpha cells from old mice. Immunostaining confirmed increased BiP protein in aged alpha cells.

Notably, this ER stress appears adaptive rather than lethal. Unlike beta cells, which lose function under chronic ER stress, aged alpha cells retained their secretory capacity at stimulatory glucose concentrations and showed apoptosis rates of only about 0.1 to 0.2 percent. Recent work suggests ER stress in alpha cells can even enhance glucagon release. The researchers also detected moderate erosion of alpha cell identity: the proportion of glucagon-positive cells expressing the master regulator Arx declined modestly, and insulin-resistant aged mice showed a higher frequency of rare bihormonal cells producing both insulin and glucagon, echoing observations in insulin-resistant humans and elderly rhesus monkeys.

Crucially, the mouse findings translated to humans. Within the CORDIOPREV clinical study, the team analyzed 462 patients without diabetes at baseline, of whom 107 developed type 2 diabetes over a median follow-up of 60 months. Older adults with insulin resistance, whether classified by biological age using telomere length or by chronological age, displayed significantly higher fasting glucagon levels and a greater glucagon secretory response during an oral glucose tolerance test than any other group. Kaplan-Meier analysis showed that while age alone already conferred a significant risk of developing diabetes, elevated glucagon levels amplified that risk further.

The study’s authors caution that several questions remain, including how systemic factors such as inflammation, senescence-associated secretory signals from neighboring beta cells, and altered paracrine regulation integrate with intrinsic alpha cell aging. But the central message is clear: alpha cells are resilient survivors of aging that paradoxically become a metabolic liability, pumping out glucagon when the body can no longer rein them in. As glucagon signaling emerges as a therapeutic target in type 2 diabetes, older adults with insulin resistance may represent the population that stands to benefit most from treatments aimed at restoring the brake on these wayward cells.

Subject of Research: Effects of aging on pancreatic alpha cell function, glucagon secretion, and age-associated type 2 diabetes risk

Article Title: Aging Affects Pancreatic α‐Cell Function and Promotes Hyperglucagonemia: Implications in Age‐Associated Diabetes

Article References: Tudurí, E., Almagro, L., Ojeda‐Rodríguez, A., Pascua‐Maestro, R., Brunetta, H. S., Soriano, S., López‐Moreno, A., Boronat‐Belda, T., Velasco‐Avilés, S., da Silva Junior, J. A., Castellano‐Muñoz, M., Rafacho, A., Cózar‐Castellano, I., Nadal, Á., Alonso‐Magdalena, P., Merino, B., López‐Miranda, J., & Quesada, I. (2026). Aging Affects Pancreatic α‐Cell Function and Promotes Hyperglucagonemia: Implications in Age‐Associated Diabetes. Aging Cell, 25(10), Article e70753. https://doi.org/10.1111/acel.70753

Image Credits: AI Generated

DOI: 10.1111/acel.70753

Keywords: pancreatic alpha cells, glucagon, aging, type 2 diabetes, insulin resistance, hyperglucagonemia, endoplasmic reticulum stress, islet architecture, CORDIOPREV study, beta cells, glucose homeostasis, Aging Cell

Glucagon is the hormonal mirror image of insulin. While insulin ushers glucose out of the bloodstream and into tissues, glucagon does the opposite, instructing the liver to release stored glucose when fasting or hypoglycemia threatens the brain’s energy supply. It is produced by alpha cells, a small but critical population within the pancreatic islets that has historically received far less attention than the insulin-secreting beta cells. In type 2 diabetes, the glucagon axis is often deranged: alpha cells fail to suppress glucagon after meals, contributing to the hyperglycemia that defines the disease, while paradoxically overreacting during hypoglycemic episodes. Understanding what drives alpha cell dysfunction has therefore become a pressing question, and the new study suggests that a circulating liver-derived protein may be part of the answer.

Fetuin-A, encoded in humans by the AHSG gene, is produced almost exclusively by hepatocytes and circulates at high concentrations in the blood. Previous research had established associations between elevated Fetuin-A levels, insulin resistance, fatty liver disease, and low-grade inflammation, but its influence on alpha cell function had never been systematically explored. To probe that gap, the investigators turned to Alpha TC1 clone 6 cells, a mouse pancreatic alpha cell line widely used to study glucagon biology. They exposed the cells to high concentrations of Fet-A under hyperglycemic conditions and then switched them to low glucose to trigger glucagon synthesis, a protocol designed to mimic the metabolic swings that alpha cells experience in vivo.

The results were striking. Fetuin-A treatment increased the expression of preproglucagon mRNA, the genetic template from which glucagon is made, indicating that the protein acts at the level of gene transcription rather than merely prompting the release of preformed hormone. Mechanistically, the team found that Fet-A activated inflammatory signaling through Toll-like receptor 4, or TLR4, the same innate immune receptor that recognizes bacterial lipopolysaccharide. When the researchers silenced the TLR4 gene using small interfering RNA, the stimulatory effect of Fetuin-A on glucagon synthesis vanished, demonstrating that the receptor is a necessary intermediary. Pharmacological inhibitors corroborated the finding, and Western blotting confirmed that the alpha cells express TLR4 basally, giving the pathway a plausible structural foothold.

But the study did not stop at inflammation. A second, and arguably more novel, mechanism emerged from the interaction between Fetuin-A and insulin-like growth factor 1, or IGF-1. Under normal circumstances, IGF-1 suppresses glucagon synthesis during hypoglycemia through the PI3K/Akt/FoxO1 signaling cascade, a well-characterized intracellular pathway that transmits growth factor signals from the cell surface to the nucleus. The researchers found that Fetuin-A disrupted this braking mechanism, impairing IGF-1’s ability to dampen glucagon production precisely when suppression matters most. In other words, when blood sugar drops and the body needs to restrain glucagon’s counter-regulatory surge, elevated Fetuin-A appears to loosen the leash.

To understand how a circulating glycoprotein could interfere with a receptor-driven pathway, the team turned to cell-surface confocal microscopy and molecular docking. The imaging experiments revealed a dose-dependent co-localization of Fetuin-A with the IGF-1 receptor on the alpha cell membrane, suggesting that the two molecules physically occupy overlapping territory. Docking analysis predicted potential structural overlap within the receptor’s extracellular domain, and sequence alignment studies showed that the relevant beta-subunit domain is spatially conserved across human and mouse insulin and IGF-1 receptors. Taken together, the data support a model of steric interference: Fetuin-A binds at or near the receptor’s ligand-binding region, physically obstructing IGF-1 from engaging its target and thereby blunting the downstream signal that normally curtails glucagon synthesis.

The cell culture findings were then tested in living organisms. The researchers administered Fetuin-A to CD-1 mice for three consecutive days, with a saline-treated control group for comparison. The treated animals showed increased circulating glucagon concentrations, along with elevated levels of inflammatory cytokines, mirroring the dual inflammatory and hormonal signature observed in the cell experiments. All animal protocols were approved by the local Animal Care Committee and conducted in accordance with European directive 2010/63/EU, the ARRIVE guidelines, and the 3R principle, lending regulatory rigor to the in vivo component of the work.

The final and most clinically consequential piece of evidence came from humans. The team analyzed data from 93 non-diabetic adults enrolled in the CATAMERI study, the CAtanzaro MEtabolic RIsk cohort, a long-running observational project examining cardiometabolic risk factors. Fasting plasma Fetuin-A concentrations were positively associated with fasting glucagon levels, and the association held up after statistical adjustment for age, sex, body mass index, insulin, and IGF-1. That independence matters: it argues that the relationship is not simply a byproduct of obesity, insulin status, or growth factor levels, but reflects a direct physiological link between the liver-derived protein and alpha cell output. Glucagon was measured using a chemiluminescence immunoassay, a sensitive and standardized method that strengthens confidence in the clinical measurement.

What emerges from the combined evidence is a coherent mechanistic story with potential implications for metabolic disease. If Fetuin-A, elevated in obesity and fatty liver, both inflames alpha cells through TLR4 and disables the IGF-1-mediated brake on glucagon synthesis, then the protein could help explain why hyperglucagonemia persists in insulin-resistant states even when glucose is abundant. The liver, in this framing, is not just a victim of hormonal miscommunication but an active participant, secreting a signal that reshapes the behavior of the very cells responsible for glucose counter-regulation. The authors also verified that Fet-A was not cytotoxic to the alpha cells across the concentration range tested, using MTT viability assays over 48 hours, which rules out the trivial explanation that the hormone changes simply reflect cell damage or death.

Cautions remain, as they always do in translational research. The cell line is murine, the mouse experiments involved exogenous protein administration rather than chronic endogenous elevation, and the human data are cross-sectional, showing association rather than causation. Whether lowering Fetuin-A would normalize glucagon levels in people with diabetes is a question for future interventional studies. Still, the convergence of evidence across three biological levels, from transcriptional regulation in cultured cells to hormone measurements in mice and statistical associations in a well-characterized human cohort, gives the hypothesis unusual solidity. The work was supported by Italian national research funding programs, including PNRR and PRIN grants, and the authors report no competing interests. As the field increasingly recognizes alpha cells as active drivers of dysglycemia rather than passive bystanders, Fetuin-A now sits squarely on the list of molecular suspects worth pursuing, and therapies aimed at interrupting its interaction with TLR4 or the IGF-1 receptor may one day earn a place in the metabolic medicine arsenal.

Subject of Research: The role of the liver-derived glycoprotein Fetuin-A in regulating pancreatic alpha cell glucagon synthesis and secretion

Article Title: Alpha 2-HS glycoprotein increases glucagon synthesis and secretion in cells, mice, and humans

Article References: Mancuso, E., Averta, C., Rubino, M., Citraro, R., Palummo, A., Servello, A., Belviso, S., Massimino, M., Mannino, G. C., De Sarro, G., Sesti, G., & Andreozzi, F. (2026). Alpha 2-HS glycoprotein increases glucagon synthesis and secretion in cells, mice, and humans. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08965-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08965-7

Keywords: Fetuin-A, glucagon, pancreatic alpha cells, TLR4, IGF-1 receptor, inflammation, insulin resistance, type 2 diabetes, liver, metabolic disease, PI3K/Akt/FoxO1, CATAMERI study

The study, led by researchers at Fujita Health University, set out to probe a long-standing puzzle in metabolic physiology. Insulin and glucagon, the two pancreatic hormones that jointly govern nutrient handling, respond very differently to protein than to carbohydrate. Glucose ingestion robustly stimulates insulin and suppresses glucagon in healthy individuals, but in type 2 diabetes the early insulin response is blunted and glucagon paradoxically rises. Protein, by contrast, stimulates both hormones in everyone, making protein a particularly potent glucagon secretagogue regardless of glycemic status. Because insulin drives amino acid uptake into peripheral tissues for protein synthesis while glucagon promotes hepatic gluconeogenesis, converting amino acids into glucose, the researchers hypothesized that the balance between these hormones, known as the insulin-to-glucagon ratio, would determine how the liver handles a sudden flood of dietary amino acids.

To test this, the team compared nondiabetic mice with mice made diabetic by injections of streptozotocin, a compound that destroys insulin-producing beta cells and produces a model of severe insulin deficiency. After an overnight fast, both groups received either a liquid normal control diet, containing roughly 67 percent carbohydrate and 15 percent protein, or a liquid high-protein diet with 58 percent protein and only 23 percent carbohydrate, matched for calories. Blood and liver samples were collected two hours after feeding, a window chosen to capture the immediate postprandial response rather than the slower transcriptional adaptation that emerges over days of high-protein feeding.

The hormonal results were revealing. In nondiabetic mice, the high-protein meal produced lower insulin and GIP secretion at 60 minutes than the control diet, an effect the authors attribute largely to the reduced carbohydrate content of the meal. Glucagon, however, rose significantly higher with the protein load. In diabetic mice, insulin secretion in response to the control diet was markedly attenuated, as expected, but the response to the high-protein diet was comparable to that of nondiabetic animals. Strikingly, despite lower insulin secretion, postprandial blood glucose was actually lower in diabetic mice given the high-protein meal than in those given the carbohydrate-rich control diet, suggesting that cutting carbohydrate from a meal can blunt glycemic excursions even when insulin secretion is impaired.

Plasma amino acid profiling then exposed a sharp divergence between the two metabolic states. The high-protein diet elevated nearly all essential amino acids, including the branched-chain amino acids leucine, isoleucine, and valine, in both diabetic and nondiabetic mice. But on the normal control diet, diabetic mice generally showed lower plasma amino acid levels than their nondiabetic counterparts, a pattern consistent with accelerated gluconeogenesis draining amino acids from the circulation. When the protein load arrived, several amino acids, including arginine, tyrosine, phenylalanine, tryptophan, and isoleucine, rose significantly higher in diabetic mice than in nondiabetic ones, hinting that the diabetic body handles a protein surge differently from the very first hours.

The liver told an even more dramatic story. In nondiabetic mice, two hours of high-protein feeding left hepatic amino acid content essentially unchanged, with glutamine the only significant increase. In diabetic mice, the same meal produced significant hepatic accumulation of alanine, aspartic acid, proline, threonine, and all three branched-chain amino acids, and the increase extended to nearly every essential amino acid except histidine. Glutamine was the lone exception, falling significantly below control levels. The combination of lower plasma levels for some amino acids and higher hepatic content in diabetic mice led the authors to conclude that amino acid uptake into the liver is accelerated in diabetic animals given a protein load, effectively overwhelming the organ’s metabolic capacity and leaving substrate pooled inside hepatic tissue.

Crucially, this accumulation occurred without any corresponding transcriptional program. Quantitative PCR of sixteen genes involved in glucose and amino acid metabolism, including gluconeogenic enzymes such as Pepck and G6pc, aminotransferases, urea cycle genes, and glutaminase, revealed almost no differences between diet groups within the two-hour window. The only significant diet-related change was Cps1 in diabetic mice. This stands in sharp contrast to the team’s earlier work showing that seven days of high-protein feeding induces robust glucagon-mediated upregulation of hepatic amino acid-catabolizing enzymes, which keeps plasma amino acids, apart from branched-chain amino acids, near normal. The new data indicate that the immediate postprandial amino acid excursion is governed by non-transcriptional mechanisms, such as altered tissue uptake and substrate diversion toward gluconeogenesis, rather than by rapid changes in enzyme gene expression.

Signaling analyses added further nuance. Western blotting of liver proteins showed that Akt phosphorylation, a readout of insulin signaling, was significantly reduced by the high-protein meal in diabetic mice, and reduced glycogen content followed the same pattern in both groups, likely reflecting the meal’s lower carbohydrate content. Yet phosphorylation of GSK3β, Akt’s downstream effector in glycogen synthesis, and of CREB, the glucagon-responsive transcription factor, were unchanged across all four groups, suggesting that the two-hour time point captures signaling dynamics whose temporal relationship to hormone levels is more complex than simple feed-forward regulation. The authors note that time-course studies will be needed to untangle these kinetics.

Metabolomics also uncovered a paradox in hepatic glycogen. Despite impaired insulin secretion and a glucagon-dominant hormonal profile, diabetic mice had higher liver glycogen than nondiabetic mice under both diets, echoing recent evidence that glucagon may contribute to postprandial glycogen repletion and that hyperglycemia itself, through sheer substrate availability, can drive glycogen accumulation even without insulin action. Meanwhile, diabetic livers showed elevated early glycolytic and gluconeogenic intermediates, including glucose 6-phosphate and fructose 6-phosphate, which the authors interpret not as inefficient metabolic flux, as reported in obese diabetic models, but as a distinct state in which overwhelming substrate availability from accumulated amino acids feeds into glucose production pathways.

The clinical implications are intriguing and carefully hedged. In type 1 diabetes, where insulin secretion is severely compromised, protein-rich meals can promote hyperglycemia by stimulating glucagon. But the present findings suggest that when residual insulin secretion is preserved, as in many cases of type 2 diabetes, high-protein, low-carbohydrate feeding enhances hepatic amino acid uptake and glucose production without raising postprandial blood glucose, because the limited carbohydrate content offsets the glucose-raising effect of glucagon-stimulated gluconeogenesis. The study also raises new questions about FGF21, a liver-derived hormone acutely lowered by the protein meal in nondiabetic mice, hinting that its secretion is rapidly tuned by dietary protein or insulin action. The authors acknowledge limitations, including the absence of fasting-baseline metabolomics, no direct measurement of glycogen turnover, and no assessment of intestinal nutrient absorption. Even so, the work delivers a memorable message: in diabetes, the liver’s first response to a protein feast is a silent traffic jam of amino acids, one that precedes and perhaps shapes the slower genetic adaptation that follows.

Subject of Research: Acute high-protein feeding and hepatic amino acid metabolism in diabetic versus nondiabetic mice

Article Title: Acute high‐protein feeding induces hepatic amino acid accumulation in diabetic male mice prior to transcriptional adaptation

Article References: Acute high‐protein feeding induces hepatic amino acid accumulation in diabetic male mice prior to transcriptional adaptation. (n.d.). https://doi.org/10.14814/phy2.71117

Image Credits: AI Generated

DOI: 10.14814/phy2.71117

Keywords: diabetes, glucagon, insulin, amino acids, liver metabolism, high-protein diet, branched-chain amino acids, gluconeogenesis, FGF21, metabolomics, streptozotocin, postprandial metabolism

Messenger RNA serves as the working copy of a gene, carrying instructions from the cell’s DNA to the protein-building machinery of the cytoplasm. For decades, these molecules were viewed as simple couriers. That view has changed dramatically with the recognition that RNA itself carries a rich assortment of chemical tags that influence how long a transcript survives, how efficiently it is translated into protein, and how it is handled by the cell’s quality-control systems. The most abundant of these internal tags is N6-methyladenosine, abbreviated m6A, a methyl group attached to a specific position on adenosine bases within the transcript.

The m6A mark is installed by a dedicated set of writer enzymes, removed by eraser enzymes, and interpreted by reader proteins that determine the consequences of the modification for each individual transcript. In this way, m6A methylation functions as a dynamic regulatory system that can reshape the protein output of a cell without any change in the underlying DNA sequence. Because the mark is reversible and responsive to cellular conditions, it provides a rapid mechanism by which cells can reprogram their behavior when the environment demands it.

Pancreatic alpha cells are one of the major endocrine cell types of the islets of Langerhans, the microscopic clusters of hormone-secreting cells embedded in the pancreas. Alpha cells produce glucagon, a hormone that raises blood glucose levels by prompting the liver to release stored sugar, and thereby acts as the physiological counterweight to insulin. While insulin-producing beta cells have dominated diabetes research for generations, alpha cells have attracted growing attention for a remarkable property: under certain conditions they can transdifferentiate, adopting features of beta cells and in some settings beginning to produce insulin. This plasticity has made alpha cells a tantalizing target for regenerative strategies aimed at restoring insulin production in diabetes.

The new work demonstrates that this plasticity is not simply a passive response to injury or stress but is actively governed by the m6A machinery. By manipulating the enzymes that write, erase, and read m6A marks in alpha cells, the researchers showed that the methylation landscape of alpha-cell messenger RNAs changes dramatically when the cells shift their identity, and that disrupting this landscape impairs the cells’ ability to adapt. The results indicate that specific transcripts required for the alpha-cell program must be properly tagged and turned over for the plasticity program to proceed, while transcripts associated with alternative cell fates are regulated in parallel.

Technically, the study combined transcriptome-wide mapping of m6A sites with single-cell analyses of islet cell identity, allowing the investigators to connect changes in RNA methylation to changes in cell state at high resolution. When the writer component of the m6A machinery was removed from alpha cells, the methylation pattern across thousands of transcripts was altered, and the cells showed an impaired capacity to undergo the transitions that characterize alpha-cell plasticity. Conversely, the data suggest that physiological cues that drive alpha cells toward new identities act in part by reshaping the m6A profile of the transcriptome, effectively opening a chemical route through which external signals reach the core regulatory circuitry of the cell.

The implications for diabetes research are considerable. Approaches that aim to convert alpha cells into insulin-producing cells have often focused on transcription factors, the master proteins that switch gene programs on and off. The new findings suggest that targeting the RNA methylation machinery could offer a complementary or even more tractable route, because the enzymes involved are druggable in principle and operate reversibly. If the m6A system can be tuned to favor the conversion of alpha cells toward a beta-like fate while preserving normal glucagon regulation, it could inform future cell-replacement therapies for both type 1 and type 2 diabetes.

Beyond diabetes, the study contributes to a broader rethinking of how cell identity is maintained and changed. Epigenetic modifications of DNA and histones have long been recognized as guardians of cellular identity, but RNA-level modifications are emerging as an equally important, and far more dynamic, layer of control. Because messenger RNA molecules turn over rapidly, adjustments to their methylation status can reshape a cell’s protein output within hours, a timescale far shorter than that required for heritable chromatin changes to take effect. This makes the m6A system well suited to mediating the fast, reversible state changes that define cellular plasticity.

The work also raises questions that will drive the next phase of research. Which specific m6A marks on which transcripts are the critical determinants of alpha-cell fate? How do the reader proteins translate the chemical code into decisions about translation and decay? And how do metabolic signals, such as fluctuations in glucose or glucagon itself, feed back onto the methylation machinery in living islets? Answering these questions will require the kind of integrative approach used in the current study, combining chemical mapping of RNA modifications with functional perturbation in physiologically relevant models.

For now, the study establishes m6A methylation as a central regulator of alpha-cell plasticity and adds the endocrine pancreas to the growing list of tissues in which RNA chemistry shapes cellular destiny. As the field of epitranscriptomics matures, findings like this one point toward a future in which the chemical language of RNA can be read, and perhaps deliberately rewritten, to treat some of the most stubborn diseases of modern medicine.

Subject of Research: The role of m6A messenger RNA methylation in regulating the plasticity and identity of pancreatic alpha cells.

Article Title: m6A mRNA methylation regulates pancreatic α-cell plasticity

Article References: De Jesus, D. F., Brown, N. K., Fogarty, G., Gabriel, G., Wang, S., Wang, S., Shrestha, L., Kendall, K., Young, L., Hu, J., Austin, J., Sabadell-Basallote, J., Kahraman, S., Xiao, L., & Kulkarni, R. N. (2026). m6A mRNA methylation regulates pancreatic α-cell plasticity. Nature Metabolism. https://doi.org/10.1038/s42255-026-01591-z

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01591-z

Keywords: m6A methylation, pancreatic alpha cells, epitranscriptomics, cell plasticity, glucagon, diabetes, RNA modifications, islets of Langerhans, transdifferentiation, Nature Metabolism, gene regulation, endocrine pancreas

Pancreatic alpha cells are best known as the body’s counterweight to insulin. While beta cells release insulin to lower blood glucose, alpha cells secrete glucagon, a hormone that raises blood sugar by mobilizing glucose stores from the liver. The tight coordination of these two hormones is fundamental to metabolic health, and its breakdown lies at the heart of both major forms of diabetes. Yet alpha cells have long lived in the shadow of their insulin-secreting neighbors. Only in recent years has the field come to appreciate that alpha cells possess their own finely tuned developmental program, a distinct epigenetic and transcriptional landscape, and a surprising capacity for plasticity, the ability to switch fate under certain pressures and transform into cells that resemble beta cells.

That plasticity is a double-edged sword. On one hand, it represents a tantalizing therapeutic opportunity: if the body’s own alpha cells can be coaxed into becoming functional beta cells, they could replace the insulin-producing cells destroyed or dysfunctional in diabetes. Previous work has shown that forced expression of transcription factors such as PDX1 and MAFA, delivered by viral gene therapy, can reprogram alpha cells into insulin-producing cells and even reverse autoimmune diabetes in mouse models. On the other hand, unplanned and incomplete fate conversion is potentially harmful. Cells caught between identities may perform neither function well, secreting inappropriate hormone combinations and destabilizing glucose control. Understanding the molecular brakes that normally prevent such drift is therefore as important as understanding the accelerators that drive it.

The new study identifies one of those brakes as a component of the cell’s RNA-processing equipment. N6-methyladenosine, commonly abbreviated m6A, is installed on mRNA by a multi-protein writer complex whose catalytic core includes the methyltransferase METTL14 together with its partner METTL3. The modification influences nearly every stage of an mRNA molecule’s life, including how it is spliced, exported from the nucleus, translated into protein, and eventually degraded. Because m6A affects the fates of thousands of transcripts simultaneously, it acts as a broad regulator of gene expression, shaping cell state without altering the underlying DNA sequence. Previous work had already shown that m6A methylation is required for human beta-cell identity and function, and that METTL14-dependent methylation governs early pancreatic endocrine differentiation, but the role of the modification in mature alpha cells remained unexplored.

To probe that question, the researchers deleted METTL14 specifically in alpha cells, stripping the cells of their capacity to deposit m6A marks on newly made mRNA. The consequences were immediate and instructive. Amino acid-stimulated glucagon secretion, the signature function of alpha cells, was impaired. Loss of the methylation machinery also destabilized the alpha-cell state itself: the expression of genes that define and sustain alpha-cell identity became disorganized, and the cells began to show features characteristic of immature, insulin-secreting, beta-cell-like fates. In other words, without its mRNA methylation marks, the alpha cell no longer reliably remembered what it was supposed to be.

The mechanistic logic is elegant. Alpha-cell identity is maintained by a network of transcription factors and regulatory RNAs whose balanced expression keeps the glucagon program active while repressing alternative fates. m6A methylation contributes to that balance by controlling the stability and translation of key transcripts. When METTL14 is lost, the methylation patterns that help enforce the alpha-cell program disappear, the network loses its grip, and plasticity pathways that are normally silenced can come to the fore. The result is a gradual shift in cell state, mirroring the fate conversions observed when developmental regulators are experimentally forced into action, but arising here from the absence of a housekeeping modification rather than the addition of a reprogramming factor.

These results extend a growing body of evidence that the epitranscriptome is not a passive decoration of RNA but an active pillar of cellular identity in the endocrine pancreas. The 2019 finding that m6A regulates human beta-cell biology in physiological states and in type 2 diabetes established the modification’s importance on the insulin-producing side of the islet. The new work completes the picture on the glucagon-producing side, showing that alpha cells depend on the same machinery to preserve their own specialized function. Together, the studies suggest that m6A methylation acts as a general safeguard of endocrine cell fate, protecting both major hormone-producing lineages of the pancreatic islet from identity erosion.

The implications for diabetes research are considerable. If loss of mRNA methylation promotes alpha-to-beta-like plasticity, then the modification could represent a checkpoint that regenerative therapies must either respect or deliberately manipulate. Strategies aimed at converting alpha cells into replacement beta cells might need to account for the destabilizing or stabilizing effects of the m6A machinery, and conversely, drugs that modulate m6A writers, erasers, or reader proteins could in principle be used to either encourage or restrain fate switching. More broadly, the work raises the possibility that some forms of islet dysfunction in diabetes may reflect age-related or stress-related decline in RNA modification pathways, a hypothesis that is now testable with the expanding toolkit of epitranscriptomic mapping methods.

The study also adds nuance to the concept of cellular plasticity itself. Rather than being triggered solely by external injury or forced transcription factor expression, fate drift can emerge from the quiet failure of an RNA-level maintenance system. This reframes alpha-cell identity as a state that must be actively and continuously renewed through post-transcriptional regulation, not merely switched on during development and left to run. The research team’s demonstration that METTL14 deletion simultaneously impairs amino acid-regulated glucagon secretion and promotes beta-like conversion links two previously separate observations, defective alpha-cell function and aberrant plasticity, into a single mechanistic framework.

For now, the immediate significance of the work is conceptual: it identifies mRNA methylation as a guardian of alpha-cell identity and provides a molecular explanation for how endocrine cells resist, or fail to resist, the pull of alternative fates. The long-term significance may prove larger. As the field continues to map the epitranscriptomic codes that stabilize or destabilize cell states, the prospect of precisely controlling cellular identity, whether to protect failing islets or to regenerate them, moves from speculation toward concrete pharmacology. The alpha cell, long considered a secondary player in diabetes biology, has now claimed a central role in that emerging story.

Subject of Research: The role of m6A mRNA methylation by METTL14 in maintaining pancreatic alpha-cell identity and preventing cellular plasticity toward beta-cell-like fates.

Article Title: mRNA methylation safeguards pancreatic α-cell identity against cellular plasticity

Article References: mRNA methylation safeguards pancreatic α-cell identity against cellular plasticity. (2026). Nature Metabolism. https://doi.org/10.1038/s42255-026-01594-w

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01594-w

Keywords: m6A methylation, METTL14, pancreatic alpha cells, epitranscriptomics, glucagon, cellular plasticity, beta cells, diabetes, gene regulation, RNA modification, islet biology, cell identity